Expert Consensus on the Diagnosis and Treatment of Hereditary Angioedema in China (2024 Edition)

遗传性血管水肿 血管性水肿 医学 皮肤病科 中国 疾病 病理 重症监护医学 政治学 法学
作者
Yingyang Xu,Shuang Liu,Xue Wang,Wei Chen,Lei Cheng,Yinshi Guo,Jingnan Li,Fang Liu,Ruiling Liu,Juan Meng,Yuemei Sun,Siqin Wang,Qingyu Wei,Yongmei Yu,Huanping Zhang,Zuotao Zhao,Huadong Zhu,Rongfei Zhu,Yuxiang Zhi
出处
期刊:International Archives of Allergy and Immunology [Karger Publishers]
卷期号:187 (1): 61-73 被引量:12
标识
DOI:10.1159/000545808
摘要

BACKGROUND: Hereditary angioedema (HAE) is a rare, life-threatening autosomal dominant disorder characterized by recurrent episodes of subcutaneous and submucosal edema. Recent years have witnessed significant advancements in HAE management globally as well as in China, including improved understanding of its pathophysiology and the development of targeted therapies. In China, since the publication of the first national consensus in 2019, accumulating clinical experience and the availability of novel therapeutic agents have created an urgent need to update diagnostic and treatment guidelines to reflect current best practices. SUMMARY: This updated 2024 consensus was developed through collaboration among multidisciplinary experts in allergy, otorhinolaryngology, gastroenterology, dermatology, and emergency medicine across China. It provides comprehensive, evidence-based recommendations for HAE-C1-INH management. This consensus refined diagnostic algorithms incorporating clinical presentation, quantitative/functional C1-INH assays, and complement C4 testing, with genetic sequencing reserved for cases with strong clinical suspicion but normal C1-INH levels/function. It stratified treatment approaches reflecting China's current therapeutic landscape: (1) on-demand therapy with icatibant, which is the only currently approved bradykinin B2 receptor antagonist in China; (2) short-term prophylaxis using androgens or fresh frozen plasma for procedural triggers; (3) long-term prophylaxis with lanadelumab which is the first-line monoclonal anti-kallikrein antibody available in China. Special considerations for pediatric, pregnant, and breast-feeding patients are also addressed. KEY MESSAGE: As the first updated consensus since 2019, this guideline standardizes HAE management across China while addressing regional disparities in diagnostic capabilities and treatment accessibility. It emphasizes early diagnosis to prevent life-threatening laryngeal edema and promotes individualized treatment strategies tailored to China's therapeutic landscape. Future directions include emerging targeted therapies and the development of biomarkers for disease severity prediction. Implementation of these recommendations is expected to significantly reduce diagnostic delays, improve patient outcomes, and enhance quality of life for individuals with HAE in China.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
秋风的应助被西柏采纳,获得10
刚刚
arcidia发布了新的文献求助10
1秒前
ljx完成签到,获得积分10
1秒前
上官若男的应助被杨茜然采纳,获得10
1秒前
3秒前
科研通AI2S的应助被独特乘云采纳,获得10
3秒前
PYF8086完成签到,获得积分10
4秒前
4秒前
5秒前
6秒前
MSN发布了新的文献求助10
6秒前
研友_LMN2rn完成签到,获得积分10
6秒前
6秒前
6秒前
7秒前
空耳大师完成签到 ,获得积分10
8秒前
9秒前
9秒前
WHW发布了新的文献求助10
9秒前
tmj发布了新的文献求助10
9秒前
Cold完成签到,获得积分10
9秒前
Jensen完成签到,获得积分10
10秒前
nature发布了新的文献求助10
10秒前
xionggege完成签到,获得积分10
10秒前
xfy发布了新的文献求助200
10秒前
11秒前
11秒前
漆漆发布了新的文献求助10
11秒前
素人完成签到,获得积分10
11秒前
壶里有水给壶里有水的求助进行了留言
12秒前
arcidia完成签到,获得积分20
12秒前
GIN的应助被迷人的老黑采纳,获得20
12秒前
七颗茶香豆关注了科研通微信公众号
12秒前
萝卜完成签到 ,获得积分20
12秒前
13秒前
13秒前
13秒前
13秒前
heaven发布了新的文献求助10
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193438
求助须知:如何正确求助?哪些是违规求助? 9579666
关于积分的说明 21866723
捐赠科研通 7793099
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560719
邀请新用户注册赠送积分活动 2484156